Draft:Mennati

= Afsaneh Mennati = She is a recent graduate of Pharmaceutical Nanotechnology PhD at Zanjan University of Medical Sciences. where she gave her Project on “Design of hybrid nanoparticles as anti IGF-1R siRNA and lycopene codelivery carrier for receptor’s gene silencing and reduction of mitogenic action of IGF-1 in breast cancer cell line (MCF-7) ”. In her research, she focused on Combination therapy and reduced expression of some genes involved in the breast cancer cell line (MCF7). She worked on proposed mPEG-PCL-DDAB as a potent nanocarrier for drug delivery to MCF-7 breast cancer cell lines, in vitro, and their applicability for the IGF-1R silencing, as a promising anti-cancer therapeutic approach, for the first time. She was able to design and synthesize a unique nanoparticle that is simultaneously used for delivering gene and drug. The nanoparticle Acute toxicity was investigated in mice and it was proven to be safe. She also researched the resistance of cancer cells to anti-cancer drugs and their treatment through gene therapy.